. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: Gastroenterology. 2019 Jul 12;157(4):933–935. doi: 10.1053/j.gastro.2019.07.012

Table 2.

Outcomes after Spacer Placement

Variables	Patient 1	Patient 2	Patient 3	Patient 4
Chemo/immunotherapy regimen	FOLFIRINOX	FOLFIRINOX, nivolumab	FOLFIRINOX, nivolumab	FOLFIRINOX
Disease progression	None	Liver metastasis	None	None
Time from hydrogel to resection	78	-	60	60
AJCC stage at resection	ypT0N0, R0	-	ypT0N0, R0	ypT1aN1, R0
Follow-up time (days)	366	161, deceased	352	331, liver metastasis at day 248 after resection

AJCC, American Joint Committee on Cancer.